FDA Signals Potential Updates to SUPAC Guidances—Comments Due June 1, 2026 March 12, 2026 By Fabiola C. Gomez, Ph.D., CMC Regulatory Expert — ++

https://www.thefdalawblog.com/2026/03/fda-signals-potential-updates-to-supac-guidances-comments-due-june-1-2026/?utm_source=rss&utm_medium=rss&utm_campaign=fda-signals-potential-updates-to-supac-guidances-comments-due-june-1-2026 The FDA has issued a notice announcing the opening of a public docket to solicit information and comments on its longstanding Scale-Up and Postapproval Changes (SUPAC) guidances for specific dosage forms. The request signals the Agency’s interest in reassessing these documents in light of evolving science and regulatory practice. HPM to Host Complimentary Webinar on US Regulatory Strategy for MedTech Startups March 6, 2026 Hyman, Phelps & McNamara, P.C. (HPM) is hosting a complimentary webinar, titled “From Prototype to Approval: US Regulatory Strategy for MedTech Startups.” The webinar is scheduled for March 25, 2026 (11:00am to 12:00pm ET). https://www.thefdalawblog.com/2026/03/hpm-to-host-complimentary-webinar-on-us-regulatory-strategy-for-medtech-startups/?utm_source=rss&utm_medium=rss&utm_campaign=hpm-to-host-complimentary-webinar-on-us-regulatory-strategy-for-medtech-startups